Evidence map›Paper›PMID 38279717›Full record

ArticleCurrent cancer drug targets2024

Novel Association of

Huiyan Deng, Yan Ding, Zhiyu Wang, Xiangdong Liang, Yueping Liu

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Huiyan DengDepartment of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Yan DingDepartment of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Zhiyu WangDepartment of Oncology Immunology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Xiangdong LiangDepartment of Urology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Yueping LiuDepartment of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMüllerian clear cell carcinoma of the male urethra is similar to that of the female genital tract in terms of morphology and immunohistochemical expression but is rarely observed in clinical practice. CASE PRESENTATION: Here, we report the case of a 65-year-old man diagnosed with Müllerian clear cell carcinoma who harboured a mutation in

conclusionThis case enhances our knowledge of the molecular biology of Müllerian clear cell carcinoma of the male urethra, which will help clinicians select optimal treatment options for this rare cancer in patients with specific driver mutations.

Indexed as

Adenocarcinoma, Clear CellMutationUrethral NeoplasmsAgedDNA HelicasesHumansMaleNuclear ProteinsDNA HelicasesNuclear Proteinsmale urethraMüllerian clear cell carcinomanext-generation sequencingprognosis.RAD54L genetreatment

Identifiers

PMID38279717
OpenAlexW4391253118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.